Rahul Sahgal – CEO, Swiss-American Chamber of Commerce
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
The Swiss-American Chamber of Commerce plays a vital and active role in assisting Swiss companies in the United States and U.S. companies in Switzerland to expand their business. The Swiss-American Chamber of Commerce is a not-for-profit organization.
Relations between Switzerland and the United States of America are extremely diverse and enjoy a rich tradition. The United States is the second largest export market for Switzerland and an important hub for education and research. Over the last 12 years, exports to America have doubled in volume, going from 10.6 to 14.5 percent of all Swiss exports between 2004 and today. Swiss pharmaceutical exports account for approximately 47 percent of trade with America.
Contact
Talacker 41, 8001 Zurich, Switzerland, Phone: +41 43 443 72 00
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a…
Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow…
In spite of the spectacular healthcare advances the world has seen in recent decades and increasing evidence that gender equality is not only an ethical necessity, but a decisive component…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment…
Sparks, the Swiss Exchange’s newly launched small and medium sized enterprise (SME) trading venue, intends to make it easier for biotech SMEs to raise capital and strengthen their profile. The…
The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly…
Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis…
Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate,…
The World Health Assembly Special Session on a Pandemic Treaty, which will convene health ministries from around the world in Geneva next week, offers a unique opportunity to take a…
Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the…
Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being…
After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted…
See our Cookie Privacy Policy Here
